[Cardiovascular effects of L-dopa and decarboxylase inhibitor on patients with Parkinson's disease].
D000368:Aged; D001281:Atrial Fibrillation / Q000139:chemically induced; D002037:Bundle-Branch Block / Q000150:complications; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D005117:Cardiac Complexes, Premature / Q000139:chemically induced; D002319:Cardiovascular System / Q000187:drug effects*; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D004569:Electroencephalography; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007022:Hypotension / Q000139:chemically induced; D008297:Male; D009203:Myocardial Infarction / Q000150:complications; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*; D013610:Tachycardia / Q000139:chemically induced
D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases
Effets cardiovasculaires de la L-dopa et de i'inhibiteur de la décarboxylase chez les malades atteints de la maladie de Parkinson.